BlackRock
AXN

BlackRock’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

BlackRock’s Portfolio AXN Stock Details AXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-36
Closed – – 3783
2015
Q4 		$0 Buy
+36
New +$45 ﹤0.01% 3545

Other funds holding AXN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
MA
MUFG Americas New York $4.04B AUM 12.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock's AXN Position: Q1 2016 in Review

BlackRock sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q1 2016, closing a stake of 36 shares.

BlackRock first reported a position in AXN in Q4 2015 and held it in 1 quarter. The position peaked at $0 in Q4 2015. 11 funds tracked by Wall St. Rank hold AXN as of Q1 2016.

  • BlackRock reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q1 2016 after selling out during the quarter.
  • BlackRock sold 36 Aoxing Pharmaceutical Company Inc. shares in Q1 2016.
  • BlackRock first reported a position in Aoxing Pharmaceutical Company Inc. in Q4 2015 and held it in 1 quarter.
  • BlackRock's Aoxing Pharmaceutical Company Inc. position peaked at $0 in Q4 2015.
  • 11 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q1 2016.

Based on BlackRock's 13F filing for Q1 2016, filed 10 May 2016.